[go: up one dir, main page]

DK3484469T3 - Sammensætninger og fremgangsmåder til potentiering af antimikrober - Google Patents

Sammensætninger og fremgangsmåder til potentiering af antimikrober Download PDF

Info

Publication number
DK3484469T3
DK3484469T3 DK17827133.4T DK17827133T DK3484469T3 DK 3484469 T3 DK3484469 T3 DK 3484469T3 DK 17827133 T DK17827133 T DK 17827133T DK 3484469 T3 DK3484469 T3 DK 3484469T3
Authority
DK
Denmark
Prior art keywords
antimicrobies
potentiation
compositions
methods
Prior art date
Application number
DK17827133.4T
Other languages
English (en)
Inventor
Ephraim Brener
Elran Haber
Adi Zuloff-Shani
Ascher Shmulewitz
Original Assignee
Scisparc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd filed Critical Scisparc Ltd
Application granted granted Critical
Publication of DK3484469T3 publication Critical patent/DK3484469T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065Diphenyl-substituted acyclic alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17827133.4T 2016-07-14 2017-07-13 Sammensætninger og fremgangsmåder til potentiering af antimikrober DK3484469T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362082P 2016-07-14 2016-07-14
PCT/IL2017/050800 WO2018011813A1 (en) 2016-07-14 2017-07-13 Compositions and methods of potentiating antimicrobials

Publications (1)

Publication Number Publication Date
DK3484469T3 true DK3484469T3 (da) 2024-06-24

Family

ID=60952228

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17827133.4T DK3484469T3 (da) 2016-07-14 2017-07-13 Sammensætninger og fremgangsmåder til potentiering af antimikrober

Country Status (9)

Country Link
US (3) US20190183914A1 (da)
EP (1) EP3484469B1 (da)
CN (3) CN119633002A (da)
CA (1) CA3068806A1 (da)
DK (1) DK3484469T3 (da)
ES (1) ES2985112T3 (da)
MA (1) MA45688A (da)
PL (1) PL3484469T3 (da)
WO (1) WO2018011813A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352855A4 (en) 2015-09-22 2019-05-22 Vitality Biopharma, Inc. CANNABINOID GLYCOSIDE PRODRUGS AND SYNTHESIS METHOD
WO2018208875A1 (en) 2017-05-09 2018-11-15 Vitality Biopharma, Inc. Antimicrobial compositions comprising cannabinoids and methods of using the same
WO2019069312A2 (en) * 2017-10-04 2019-04-11 Euro Dent Bvba SYSTEM FOR DETECTING INTRABUCCAL DISEASE AND DETERMINING A CUSTOMIZED TREATMENT SCHEME AND METHOD FOR PRODUCING THE SAME
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
WO2020051284A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
US20210379010A1 (en) * 2018-10-30 2021-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions comprising cannabinoids for use in the treatment of biofilm and conditions associated with microbial, fungal, bacterial infections
GB2581987B (en) * 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
EP3946315A4 (en) * 2019-03-28 2023-04-12 Scicann Therapeutics Inc. CANNABINOID COMPOSITIONS AND THEIR USE
CN109758441A (zh) * 2019-03-29 2019-05-17 广东工业大学 N-脂肪酰基乙醇胺类化合物在制备抑制细菌群体感应系统的药物中的应用和药物
CN113710263A (zh) 2019-05-06 2021-11-26 大不列颠哥伦比亚大学 抗生大麻素-萜烯制剂
EP3986395A4 (en) * 2019-06-18 2023-08-09 Botanix Pharmaceuticals Ltd ANTIBACTERIAL DOSAGE REGIMEN USING CANNABINOIDS
WO2020263975A1 (en) 2019-06-24 2020-12-30 Diverse Biotech, Inc. Beta-lactam-cannabinoid conjugate molecules
CN110973159B (zh) * 2019-10-30 2021-04-06 广州市浪奇实业股份有限公司 一种含有大麻二酚的抗菌组合物及其应用
EP4065094A1 (en) * 2019-11-29 2022-10-05 Botanix Pharmaceuticals Ltd Antibacterial treatment using a cannabinoid and an active agent
CN112195558A (zh) * 2020-09-24 2021-01-08 上海丰格无纺布有限公司 一种抗微生物无纺布及其制备方法
WO2023130142A2 (en) * 2022-01-03 2023-07-06 Bryant Cynthia W Compositions and methods using cannabinoid compounds for treating urinary tract disorders
WO2024159198A2 (en) * 2023-01-27 2024-08-02 Nagy Aurangzeb Nafees Compositions and methods using tetrahydrocannabinol and compositions including same for treating indications involving inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US20050054730A1 (en) 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
WO2009158499A2 (en) * 2008-06-25 2009-12-30 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
CN103361820A (zh) * 2012-03-30 2013-10-23 太仓棨淂服装有限公司 一种抗菌牛仔面料
EP3049076A4 (en) * 2013-09-26 2018-04-18 Ronald D. Sekura Topical treatments incorporating cannabis sp. derived botanical drug product

Also Published As

Publication number Publication date
CN119633002A (zh) 2025-03-18
PL3484469T3 (pl) 2024-08-19
CN109562094A (zh) 2019-04-02
CA3068806A1 (en) 2018-01-18
EP3484469A1 (en) 2019-05-22
EP3484469A4 (en) 2020-07-22
US20230045747A1 (en) 2023-02-09
US11491172B2 (en) 2022-11-08
WO2018011813A1 (en) 2018-01-18
US20210093652A1 (en) 2021-04-01
EP3484469B1 (en) 2024-05-22
CN119770661A (zh) 2025-04-08
ES2985112T3 (es) 2024-11-04
MA45688A (fr) 2019-05-22
US20190183914A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3356529T3 (da) Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3519572T5 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3389636T3 (da) Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme